Welcome to our dedicated page for Schrodinger news (Ticker: SDGR), a resource for investors and traders seeking the latest updates and insights on Schrodinger stock.
Schrodinger, Inc. (symbol: SDGR) is a top-tier provider of state-of-the-art molecular simulations and enterprise software solutions, catering primarily to the pharmaceutical, biotechnology, and materials science industries. With its pioneering software, Schrodinger empowers scientists to accelerate research and development, cut down on research expenses, and make groundbreaking discoveries that might not be feasible otherwise.
Established in 1990, Schrodinger has continually invested in fundamental research, leading to numerous scientific breakthroughs in drug discovery and materials science. The company's researchers have contributed hundreds of peer-reviewed scientific publications, often cited as significant works in their respective fields.
Schrodinger operates through two main segments: Software and Drug Discovery. The Software segment focuses on selling advanced software that revolutionizes drug discovery across the life sciences industry. It also caters to customers in materials science. The Drug Discovery segment generates revenue from a portfolio of preclinical and clinical programs, both internally developed and through collaborations.
Schrodinger has established profound partnerships and collaborations with companies in biotechnology, pharmaceuticals, chemicals, and electronics. One notable collaboration is with Nimbus Therapeutics, a biotech firm co-founded by Schrodinger. The company's global presence includes operations in the U.S., Europe, Japan, and India.
Recent achievements highlight Schrodinger's continuous innovation and success. The predictive power of its software solutions has led to significant advancements in scientific research, enhancing the efficiency and efficacy of drug discovery processes. Schrodinger's commitment to excellence and scientific integrity ensures it remains at the forefront of its industry, driving forward the boundaries of what is possible in molecular simulations and drug discovery.
Schrödinger (Nasdaq: SDGR) is set to release its first quarter 2023 financial results on May 4, 2023, after market close. A conference call will follow at 4:30 p.m. ET. Investors can access the live webcast on the company's website and by phone using conference ID 21402709. Schrödinger employs a physics-based computational platform to expedite the discovery of new therapeutics and materials, significantly reducing time and costs compared to traditional methods. Founded in 1990, the company has around 800 employees and collaborates with clients across more than 70 countries. To explore further, visit www.schrodinger.com.
Schrödinger, Inc. (Nasdaq: SDGR) announced the granting of stock options and restricted stock units (RSUs) to new employees as part of its 2021 Inducement Equity Incentive Plan. On April 14, 2023, the company issued a non-statutory stock option for 2,400 shares with an exercise price of $27.49, equal to the closing stock price on that date. Additionally, 1,800 RSUs were granted. Both grants are intended to facilitate employee retention and motivation, with vesting schedules over four years. Schrödinger utilizes a physics-based computational platform to expedite drug and material discovery, serving global biopharmaceutical, industrial, and academic sectors. Founded in 1990, it employs approximately 800 individuals and collaborates with organizations in over 70 countries.
Schrödinger, Inc. (Nasdaq: SDGR) announced the granting of stock options to 10 newly hired employees on
Schrödinger, Inc. (Nasdaq: SDGR) reported a 31% increase in total revenue for 2022, reaching $181.0 million. In Q4 2022, total revenue rose by 23% to $56.8 million, driven by a 24% increase in software revenue, totaling $47.8 million. Drug discovery revenue nearly doubled year-over-year to $45.4 million. The company expects continued growth in 2023, projecting software revenue growth of 13-17% and drug discovery revenue of $70-90 million. Operating expenses for 2022 stood at $247.8 million, with a net loss of $149.2 million. Despite challenges, Schrödinger is advancing its drug pipeline and improving financial metrics.
Schrödinger, Inc. (Nasdaq: SDGR) announced on
Schrödinger Inc. (Nasdaq: SDGR) reported a cash distribution of
Schrödinger (Nasdaq: SDGR) will announce its fourth quarter and full-year 2022 financial results on February 28, 2023, after market close. A conference call and webcast will follow at 4:30 p.m. ET. Interested participants can access the live webcast under 'News & Events' on Schrödinger's investor website. The company leverages its physics-based computational platform to revolutionize drug and material discoveries, with partnerships worldwide. Founded in 1990, Schrödinger employs over 800 staff and collaborates in more than 70 countries.
FAQ
What is the current stock price of Schrodinger (SDGR)?
What is the market cap of Schrodinger (SDGR)?
What does Schrodinger, Inc. do?
When was Schrodinger, Inc. founded?
What are the main segments of Schrodinger’s business?
How does Schrodinger generate revenue?
What industries does Schrodinger’s software cater to?
What are some of Schrodinger’s recent achievements?
Where are Schrodinger’s operations located?
What is Nimbus Therapeutics?
How has Schrodinger contributed to scientific research?
What makes Schrodinger's software unique?
